DK2726507T3 - Antistof mod det prostata-specifikke stamcelleantigen samt dets anvendelse - Google Patents
Antistof mod det prostata-specifikke stamcelleantigen samt dets anvendelse Download PDFInfo
- Publication number
- DK2726507T3 DK2726507T3 DK12729996.4T DK12729996T DK2726507T3 DK 2726507 T3 DK2726507 T3 DK 2726507T3 DK 12729996 T DK12729996 T DK 12729996T DK 2726507 T3 DK2726507 T3 DK 2726507T3
- Authority
- DK
- Denmark
- Prior art keywords
- ser
- gly
- antibody
- thr
- lys
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (14)
1. Til prostata-specifikt stamcelleantigen bindende antistof, hvori - de komplementaritetsbestemmende regioner (CDR) i den lette kædes variable region omfatter følgende aminosyresekvenser: CDR1 SEQ ID No. 1, CDR2 SEQ ID i No. 2, CDR3 SEQ ID No. 3, og - CDR'erne i den tunge kædes variable region omfatter følgende aminosyresekvenser: CDR1 SEQ ID No. 4, CDR2 SEQ ID No. 5, CDR3 SEQ ID No. 6.
2. Antistof ifølge krav 1, hvis variable regioner har en humaniseret aminosyresequens.
3. Antistof ifølge krav 1 eller 2, omfattende mindst to forskellige bindingsenheder, hvori i - mindst en af bindingsenhederne binder sig til et prostata-specifikt stamcelleantigen og omfatter de i krav 1 definerede komplementaritetsbestemmende regioner, og - mindst en anden af bindingsenhederne binder sig specifikt til at andet antigen end prostata-specifikt stamcelleantigen. I
4. Antistof ifølge krav 3, hvori den anden bindingsenhed binder sig specifikt til en overfladestruktur på en effektorcelle, idet bindingsenheden fortrinsvis er valgt blandt en bindingsenhed i et til en effekto reel I es overfladestruktur bindende antistof eller en sådan ligand.
5. Antistof ifølge krav 4, hvori effekto reel len er valgt blandt T-lymfocytter, NK-cellen og monocytter, fortrinsvis T-lymfocytter.
6. Antistof ifølge krav 3, hvori den anden bindingsenhed binder sig specifikt til et I 10 til 50 aminosyrer langt peptid, fortrinsvis et peptid med en aminosyresekvens der svarer til en 10 til 50 aminosyrer lang delsekvens af det humane La-protein, især et peptid med en af aminosyresekvenserne ifølge SEQ ID No. 75 eller SEQ ID No. 76.
7. Antistof ifølge et af kravene 3 til 6 i form af et diabody, triabody eller tetrabody.
8. Antistof ifølge et af kravene 1 til 7 til anvendelse som lægemiddel, især til behandling af tumorsygdomme, fortrinsvis prostatacancer, ellersom diagnostisk middel.
9. Nukleinsyre, hvis nukleotidsekvens koder for et rekombinant antistof ifølge et af kravene 1 til 7.
10. Vektor indeholdende en nukleotidsekvens ifølge krav 9.
11. Værtscelle eller ikke-human værtsorganisme indeholdende en nukleotidsekvens ifølge krav 9 eller en vektor ifølge krav 10.
12. Farmaceutisk sammensætning indeholdende et rekombinant antistof ifølge et af kravene 1 til 7 i forbindelse med et farmaceutisk acceptabelt fortyndingsmiddel eller bærestof, fortrinsvis i en til intravenøs indgivelse egnet form.
13. Farmaceutisk sammensætning ifølge krav 12, indeholdende mindst to forskellige rekombinante antistoffer, deraf mindst et antistof ifølge et af kravene 1 til 7 og mindst et andet rekombinant antistof, der indgår en specifik binding med antistoffet ifølge et af kravene 1 til 7.
14. Diagnostisk sammensætning indeholdende et rekombinant antistof ifølge et af kravene 1 til 7.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102011118022.6A DE102011118022B4 (de) | 2011-06-30 | 2011-06-30 | Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung |
| PCT/EP2012/062716 WO2013001065A1 (de) | 2011-06-30 | 2012-06-29 | Antikörper gegen das prostata-spezifische stammzellantigen und dessen verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2726507T3 true DK2726507T3 (da) | 2019-03-11 |
Family
ID=46384405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12729996.4T DK2726507T3 (da) | 2011-06-30 | 2012-06-29 | Antistof mod det prostata-specifikke stamcelleantigen samt dets anvendelse |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9200078B2 (da) |
| EP (2) | EP2726507B1 (da) |
| JP (4) | JP2014528696A (da) |
| AU (1) | AU2012277784B2 (da) |
| CY (1) | CY1121249T1 (da) |
| DE (1) | DE102011118022B4 (da) |
| DK (1) | DK2726507T3 (da) |
| ES (1) | ES2711978T3 (da) |
| HR (1) | HRP20190289T1 (da) |
| HU (1) | HUE042008T2 (da) |
| LT (1) | LT2726507T (da) |
| PL (1) | PL2726507T3 (da) |
| PT (1) | PT2726507T (da) |
| RS (1) | RS58448B1 (da) |
| SI (1) | SI2726507T1 (da) |
| TR (1) | TR201901991T4 (da) |
| WO (1) | WO2013001065A1 (da) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102011118022B4 (de) * | 2011-06-30 | 2018-01-18 | Gemoab Monoclonals Gmbh | Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung |
| ES2688035T3 (es) | 2014-08-29 | 2018-10-30 | Gemoab Monoclonals Gmbh | Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes |
| CA3221995C (en) | 2017-02-08 | 2024-05-28 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| KR20240060739A (ko) | 2017-02-20 | 2024-05-08 | 드래곤플라이 쎄라퓨틱스, 인크. | Her2, nkg2d 및 cd16에 결합하는 단백질 |
| WO2019066093A1 (ko) * | 2017-09-26 | 2019-04-04 | 주식회사 와이바이오로직스 | Scf 특이적 항체 |
| MX2020008336A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Dominios variables de anticuerpos que se dirigen al receptor nkg2d. |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6541212B2 (en) * | 1997-03-10 | 2003-04-01 | The Regents Of The University Of California | Methods for detecting prostate stem cell antigen protein |
| WO1998040403A1 (en) * | 1997-03-10 | 1998-09-17 | The Regents Of The University Of California | Psca: prostate stem cell antigen |
| DK1226177T3 (da) * | 1999-10-29 | 2008-10-06 | Genentech Inc | Antistofsammensætninger mod anti-prostata stamcelle-antigen (PSCA) og anvendelser deraf |
| ES2358427T3 (es) * | 2003-10-16 | 2011-05-10 | Micromet Ag | Elementos de unión a cd-3 desinmunizados multiespecíficos. |
| WO2005118864A2 (en) * | 2004-05-28 | 2005-12-15 | Agensys, Inc. | Antibodies and related molecules that bind to psca proteins |
| WO2009032949A2 (en) * | 2007-09-04 | 2009-03-12 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection |
| BRPI0919840B1 (pt) * | 2008-10-01 | 2023-02-28 | Amgen Research (Munich) Gmbh | Molécula de anticorpo de cadeia única biespecífica, seu uso, e composição farmacêutica que a compreende |
| US20110142811A1 (en) * | 2009-12-16 | 2011-06-16 | Deutsches Krebsforschungszentrum | Measles virus for the elimination of unwanted cell populations |
| DE102011118022B4 (de) * | 2011-06-30 | 2018-01-18 | Gemoab Monoclonals Gmbh | Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung |
-
2011
- 2011-06-30 DE DE102011118022.6A patent/DE102011118022B4/de not_active Expired - Fee Related
-
2012
- 2012-06-29 PL PL12729996T patent/PL2726507T3/pl unknown
- 2012-06-29 DK DK12729996.4T patent/DK2726507T3/da active
- 2012-06-29 EP EP12729996.4A patent/EP2726507B1/de active Active
- 2012-06-29 EP EP18207370.0A patent/EP3505536B1/de active Active
- 2012-06-29 LT LTEP12729996.4T patent/LT2726507T/lt unknown
- 2012-06-29 TR TR2019/01991T patent/TR201901991T4/tr unknown
- 2012-06-29 JP JP2014517736A patent/JP2014528696A/ja active Pending
- 2012-06-29 ES ES12729996T patent/ES2711978T3/es active Active
- 2012-06-29 HU HUE12729996A patent/HUE042008T2/hu unknown
- 2012-06-29 PT PT12729996T patent/PT2726507T/pt unknown
- 2012-06-29 WO PCT/EP2012/062716 patent/WO2013001065A1/de active Application Filing
- 2012-06-29 US US14/129,933 patent/US9200078B2/en active Active
- 2012-06-29 RS RS20190218A patent/RS58448B1/sr unknown
- 2012-06-29 AU AU2012277784A patent/AU2012277784B2/en active Active
- 2012-06-29 SI SI201231523T patent/SI2726507T1/sl unknown
-
2017
- 2017-01-12 JP JP2017002983A patent/JP6549622B2/ja active Active
-
2019
- 2019-02-11 CY CY20191100176T patent/CY1121249T1/el unknown
- 2019-02-13 HR HRP20190289TT patent/HRP20190289T1/hr unknown
- 2019-06-26 JP JP2019117977A patent/JP6886491B2/ja active Active
-
2021
- 2021-05-13 JP JP2021081553A patent/JP7341185B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DE102011118022A1 (de) | 2013-01-03 |
| CY1121249T1 (el) | 2020-05-29 |
| JP6549622B2 (ja) | 2019-07-24 |
| HRP20190289T1 (hr) | 2019-05-03 |
| JP7341185B2 (ja) | 2023-09-08 |
| EP2726507B1 (de) | 2018-11-21 |
| DE102011118022B4 (de) | 2018-01-18 |
| TR201901991T4 (tr) | 2019-03-21 |
| JP2017104113A (ja) | 2017-06-15 |
| PT2726507T (pt) | 2019-02-26 |
| EP3505536B1 (de) | 2024-08-07 |
| US9200078B2 (en) | 2015-12-01 |
| EP3505536C0 (de) | 2024-08-07 |
| AU2012277784A1 (en) | 2014-02-06 |
| EP2726507A1 (de) | 2014-05-07 |
| WO2013001065A1 (de) | 2013-01-03 |
| LT2726507T (lt) | 2019-04-10 |
| AU2012277784B2 (en) | 2015-08-20 |
| JP2014528696A (ja) | 2014-10-30 |
| EP3505536A1 (de) | 2019-07-03 |
| SI2726507T1 (sl) | 2019-05-31 |
| JP2021121201A (ja) | 2021-08-26 |
| ES2711978T3 (es) | 2019-05-08 |
| US20140134155A1 (en) | 2014-05-15 |
| RS58448B1 (sr) | 2019-04-30 |
| HUE042008T2 (hu) | 2019-06-28 |
| JP2019193652A (ja) | 2019-11-07 |
| JP6886491B2 (ja) | 2021-06-16 |
| PL2726507T3 (pl) | 2019-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102712254B1 (ko) | 개선된 항원 결합 수용체 | |
| KR101837053B1 (ko) | 종간 특이적 ＰＳＣＡｘＣＤ３, ＣＤ19ｘＣＤ3, ｃ-ＭＥＴｘＣＤ3, 엔도시알린ｘＣＤ3, ＥｐＣＡＭｘＣＤ3, ＩＧＦ-1ＲｘＣＤ3 또는 ＦＡＰαｘＣＤ3 이중특이적 단일쇄 항체 | |
| JP7341185B2 (ja) | 前立腺特異幹細胞抗原に対する抗体およびその使用 | |
| KR101820535B1 (ko) | 종간특이적 ｐｓｍａｘｃｄ3 이중특이적 단일쇄 항체 | |
| KR101940944B1 (ko) | 종간 특이적 ｃｄ３―입실론 결합 도메인 | |
| KR101671039B1 (ko) | 항 ｃｘｃｒ4 항체 및 그들의 암의 치료를 위한 용도 | |
| KR20180050321A (ko) | 분자를 표적화하기 위한 항원 결합 구조체 | |
| JP2023093642A (ja) | モジュラー四価二重特異性抗体プラットフォーム | |
| KR20230024984A (ko) | Cd70-지시 암 면역요법용 유전적으로 변형된 자연 살해 세포 | |
| KR20190133017A (ko) | 개선된 항원 결합 수용체 구성 | |
| KR20100016206A (ko) | 종간 특이적 ｃｄ３―입실론 결합 도메인 | |
| KR20220035367A (ko) | 항-dll3 키메라 항원 수용체 및 이의 용도 | |
| JP2023547447A (ja) | 改良型抗原結合受容体 | |
| KR20200041377A (ko) | Strep-tag 특이적 결합 단백질 및 그 용도 | |
| KR20210143096A (ko) | Cd22에 특이적인 항체 및 이의 용도 | |
| CN113423720A (zh) | CAR文库和scFv的制造方法 | |
| RU2825816C2 (ru) | Улучшенные антигенсвязывающие рецепторы | |
| KR20220143904A (ko) | 사람 4-1bb 항진제 항체 및 이의 사용 방법 | |
| CN116018351A (zh) | 靶向cd123的抗体、嵌合抗原受体及其用途 | |
| Marshall | Towards cancer immunotherapy: Analysis of a tumor targeting antibody and engineering of a novel fusion protein to activate cytotoxic T cells |